Recent And Upcoming FDA Advisory Committee Meetings
Executive Summary
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
You may also be interested in...
FibroGen’s Roxadustat Rejected By US FDA Panel Due To Safety Concerns, Untested Dosing Strategy
But advisory committee members see a potential opportunity for the oral anemia drug in small percentage of dialysis-dependent patients not responsive to erythropoiesis-stimulating agents; FibroGen’s revised dosing algorithm, aimed at slowing hemoglobin rate of increase and reducing risk of thrombosis, needs to be clinically tested before marketing approval, panelists said.
Incyte’s Retifanlimab Tests US FDA’s Tolerance For Low Response Rates In Accelerated Approval
US FDA advisory committee votes 13-4 to wait for Phase III data in anal cancer, expected in 2025.
Ulta Beauty Leadership Offers 2023 Holiday Outlook, AI Update In Q3 Earnings Call
The US’ biggest beauty retailer is targeting fiscal 2023 net sales between $11.1bn and $11.15bn, with comparable sales growth of 5% to 5.5%, and is optimistic about 2024 and longer-term strategies. CEO David Kimbell addressed analyst questions on the 2023 holiday season, AI and other points of interest during the firm’s third-quarter earnings call.